New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 14, 2014
04:55 EDTXLRN, XLRN, XLRN, AGIO, AGIO, AGIO, ALKS, ALKS, ALKS, ALNY, ALNY, ALNY, ARIA, ARIA, ARIA, EPZM, EPZM, EPZM, IMGN, IMGN, IMGN, TSRO, TSRO, TSROLeerink to hold a bus tour
Boston Biopharma Bus Tour travels throughout Boston on May 14-16.
News For XLRN;AGIO;ALKS;ALNY;ARIA;EPZM;IMGN;TSRO From The Last 14 Days
Check below for free stories on XLRN;AGIO;ALKS;ALNY;ARIA;EPZM;IMGN;TSRO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 19, 2014
09:05 EDTIMGNImmunoGen discloses Chief Medical Officer James O'Leary's intention to leave
Subscribe for More Information
September 18, 2014
17:57 EDTARIAARIAD CEO buys 25K shares of company stock
Subscribe for More Information
09:31 EDTXLRNAcceleron management to meet with JMP Securities
Subscribe for More Information
07:49 EDTALNYAlnylam resumed with an Outperform at Leerink
Subscribe for More Information
September 16, 2014
08:02 EDTALNYAlnylam presents ALN-CC5 pre-clinical data
Subscribe for More Information
September 15, 2014
08:05 EDTEPZMEpizyme names Peter Ho as Chief Development Officer
Epizyme announced the appointments of Peter Ho, M.D., Ph.D., as Chief Development Officer and Michael Shih, J.D. as Vice President, Business Development. Ho will lead Epizymeís clinical development, regulatory and translational medicine functions. Shih will lead Epizymeís partnership strategy and execution.
08:01 EDTALNYAlnylam names Karen Anderson as SVP, Chief Human Resources Officer
Subscribe for More Information
07:55 EDTALKSAlkermes shares attractive ahead of Q1 catalysts, says Leerink
Leerink says its recent meeting with Alkermes management confirmed its conviction that the company is executing on its growth strategy. Leerink believes clinical trials for ALKS 8700 in multiple sclerosis, ALKS 7106 in abuse deterrent opiate analgesic and the Phase II trial for ALKS 3831 in schizophrenia are all billion dollar market opportunities that are not reflected in the current stock price. The firm finds the stock attractively valued ahead of clinical data readouts that start in early Q1 of 2015. It reiterates an Outperform rating on Alkermes with a $66 price target.
07:21 EDTALNYHeart Failure Society of America to hold annual meeting
Subscribe for More Information
September 12, 2014
10:00 EDTEPZMOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:02 EDTALNYAlnylam broadens pipeline with ALN-AGT
Alnylam Pharmaceuticals announced that it is broadening its pipeline with ALN-AGT. In a poster presented at the American Heart Associationís High Blood Pressure Research 2014 Scientific Sessions, Alnylam and collaborators at the Charite Universitatsmedizin in Berlin presented results of an ALN-AGT lead molecule in an established preeclamptic rodent model. The study showed that administration of ALN-AGT resulted in knockdown of maternal AGT in the liver without detectable evidence of fetal drug exposure, significantly improved pregnancy-related hypertension, ameliorated preeclamptic sequelae in the mother such as proteinuria, and improved fetal outcomes.
05:27 EDTEPZMEpizyme initiated with a Buy at Mizuho
Target $35.
September 11, 2014
16:16 EDTAGIOBB Biotech reports 5.1% passive stake in Agios Pharmaceuticals
Subscribe for More Information
September 10, 2014
09:20 EDTTSROTESARO management to meet with Leerink
Subscribe for More Information
September 9, 2014
09:45 EDTIMGNImmunoGen management to meet with Leerink
Subscribe for More Information
06:51 EDTALKSAlkermes management to meet with Leerink
Subscribe for More Information
September 8, 2014
14:06 EDTXLRNAcceleron management to meet with Leerink
Subscribe for More Information
12:22 EDTTSROOPKO reports licensee TESARO submits NDA for Rolapitant
Subscribe for More Information
08:10 EDTTSROTESARO submits rolapitant NDA to FDA
TESARO announced that it has submitted the New Drug Application, or NDA, for oral rolapitant to the FDA. Rolapitant is an investigational neurokinin-1 receptor antagonist developed for the prevention of chemotherapy-induced nausea and vomiting.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use